Your session is about to expire
← Back to Search
Stem Cell Therapy
Wharton's Jelly Injections for Knee Osteoarthritis
Phase < 1
Recruiting
Research Sponsored by R3 Medical Research
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Diagnosed with Grade II or III OA on the KL scale (in one knee)
Be over age 30
Must not have
Have had an intra-articular injection of any drug including viscosupplementation in the index knee in the past 6 months
Be on immunosuppressive medications
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 24 hours after intervention, 1 week, 6 weeks, 3 months, 6 months, 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is a small initial study that will look at the safety and feasibility of using Wharton's Jelly allograft injections in patients with knee osteoarthritis. Participants will be divided into three
Who is the study for?
This trial is for individuals with knee osteoarthritis who are interested in trying a new treatment involving injections. Participants will be chosen randomly to receive one of three different doses of the injection.
What is being tested?
The study is testing the safety and how well people can tolerate Wharton's Jelly (WJ) allograft tissue injected into the knee at low, medium, or high doses. It's an early-stage trial to see if this could be a feasible treatment for osteoarthritis.
What are the potential side effects?
Since it’s a pilot study focusing on safety and feasibility, specific side effects aren't listed but may include typical injection-related reactions such as pain, swelling, or infection at the injection site.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
My knee has moderate to severe arthritis.
Select...
I am over 30 years old.
Select...
My pain level is 4 or higher on a scale of 0-10.
Select...
I am a woman who is not currently able to become pregnant.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have not had any knee injections in the last 6 months.
Select...
I am taking medications that suppress my immune system.
Select...
I am planning to have surgery during the study.
Select...
I am not pregnant, breastfeeding, or planning to become pregnant during the study.
Select...
I have a history of organ transplant, rheumatoid arthritis, or an autoimmune disorder.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ baseline, 24 hours after intervention, 1 week, 6 weeks, 3 months, 6 months, 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 24 hours after intervention, 1 week, 6 weeks, 3 months, 6 months, 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Alanine Transaminase
Albumin
Alkaline Phosphatase
+5 moreSecondary study objectives
36-Item Short Form Survey (SF-36)
Knee Injury and Osteoarthritis Outcome Score
Numerical Pain Rating Scale (NPRS)
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
3Treatment groups
Active Control
Group I: 2cc WJ Allograft (Low Dose)Active Control1 Intervention
The 2cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the Low Dose Group.
Group II: 3cc WJ Allograft (Medium Dose)Active Control1 Intervention
The 3cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the Medium Dose Group.
Group III: 4cc WJ Allograft (High Dose)Active Control1 Intervention
The 4cc Whartons Jelly Allograft group receives an intra-articular knee injection and is considered the High Dose Group.
Find a Location
Who is running the clinical trial?
R3 Medical ResearchLead Sponsor
1 Previous Clinical Trials
100 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger